-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RROMm/Gf++YxKNLe3HDCZ6xD5LSvdobsKfgTvIXyTp0TKyyUIyfLbCjDCj2Ixluv Y+DvOSX4/P72SNXqkpxfqw== 0001157523-04-004813.txt : 20040514 0001157523-04-004813.hdr.sgml : 20040514 20040514070113 ACCESSION NUMBER: 0001157523-04-004813 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040514 ITEM INFORMATION: FILED AS OF DATE: 20040514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23413 FILM NUMBER: 04804487 BUSINESS ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 1-781-398-0700 MAIL ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 8-K 1 a4640244.txt INTERLEUKIN GENETICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ______________ Date of Report (Date of earliest event reported): May 14, 2004 ------------ Interleukin Genetics, Inc. -------------------------- (Exact name of registrant as specified in its charter) Delaware 000-23413 94-3123681 - -------------------- ------------------- ---------------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No.) incorporation) 94-3123681 135 Beaver Street, Waltham, MA 02452 -------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 398-0700 -------------- Not Applicable ------------------------------------------------------------- (Former name or former address, if changed since last report) 1 Item 12. Disclosure of Results of Operations and Financial Condition. The following exhibits are furnished with this report: Exhibit Number Description - -------------- ------------ 99.1 Press Release dated May 14, 2004 On May 14, 2004, the Registrant issued a press release to report its financial results for the quarter ended March 31, 2004. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Interleukin Genetics, Inc. -------------------------- (Registrant) Date: May 14, 2004 /s/ Fenel M. Eloi -------------------------- Fenel M. Eloi Chief Operating Officer, Chief Financial Officer, Treasurer and Secretary 3 EX-99 2 a4640244_ex991.txt INTERLEUKIN GENETICS, INC. PRESS RELEASE Exhibit 99.1 Interleukin Genetics Reports First Quarter Financial Results WALTHAM, Mass.--(BUSINESS WIRE)--May 14, 2004--Interleukin Genetics, Inc. (OTCBB: ILGN) a leader in the development of personalized health products, today reported revenues of $645,000 and net loss of $929,000 or $0.04 per basic and diluted share for the quarter ended March 31, 2004. Key Milestones Achieved During First Quarter of 2004: In February 2004, the Company signed a Distribution agreement with Access Business Group International LLC, a subsidiary of Alticor Inc., for a firm minimum order of DNA-based risk assessment tests to be delivered in the first year of product launch. This minimum order, together with other financial performance criteria, triggered a milestone payment of $2,000,000 to the Company from Alticor. Financial Results: Revenues for the quarter were $645,000 compared to $29,000 in the same quarter of 2003. This increase was due entirely to $637,000 in research funding related to the research agreement with Alticor. For the quarter, the Company reported a net loss of $929,000 or $0.04 per basic and diluted share as compared to a net loss of $1,666,000 or $0.07 per basic and diluted share for the same period last year. "We expect 2004 to be a year during which we will make great strides in transforming Interleukin from a research and development company into an operating company," stated Dr. Philip R. Reilly, the company's Chairman and CEO. "During this year, we expect to: 1) advance the development of personalized nutritional products with Alticor, 2) build a clinical laboratory to process the tests associated with these personalized nutritional products, 3) continue the development of additional DNA-based personalized products and 4) continue the development of our science, both as part of our own commercial strategy and in conjunction with Alticor." Research and development expenditures were $381,000 in the quarter ended March 31, 2004 compared to $872,000 in the quarter ended March 31, 2003. The decrease in R&D expenses reflects a re-allocation of internal resources from internally-funded projects to the research project funded by Alticor and which are now reported as cost of revenues. Selling, general and administrative expenses were essentially constant at $683,000 for the quarter ended March 31, 2004 compared to $693,000 during the same quarter last year. As of March 31, 2004, the Company reported total assets of $7,073,000, including $6,495,000 in cash and cash equivalents as compared to total assets of $5,548,000 including $4,759,000 in cash and cash equivalents as of December 31, 2003. The increase in cash reflects the $2,000,000 milestone payment received from Alticor in March 2004. About Interleukin Interleukin Genetics is a biotechnology company focused on inflammation. The company uses functional genomics to help in the development of risk assessment, nutritional and therapeutic products based on the genetic variations in people to help prevent, ameliorate or treat diseases involving inflammation. Interleukin's current programs focus on cardiovascular disease, osteoporosis, rheumatoid arthritis and Alzheimer's disease. Interleukin expects that these programs will produce products that will personalize the selection of nutritional and therapeutic products and enable the managed care industry to improve patient care and better allocate resources. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com. Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop risk assessment, nutritional and therapeutic products based on the genetic variations in people to help prevent, ameliorate or treat diseases of inflammation, our ability to product products that will personalize the selection of nutritional and therapeutic products to enable the managed care industry to improve patient care and better allocate resources, our ability to construct a DNA testing infrastructure, our ability to screen nutritional compounds for their effects on inflammatory responses, given specific IL-1 genetic patterns, our ability to develop new DNA-based tests, our ability to make progress in advancing our science and our ability to launch new commercial products by 2005. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to develop risk assessment, nutritional and therapeutic products based on the genetic variations in people to help prevent ameliorate or treat diseases of inflammation, our ability to product products that will personalize the selection of nutritional and therapeutic products to enable the managed care industry to improve patient care and better allocate resources our ability to construct a DNA testing infrastructure, our ability to screen nutritional compounds for their effects on inflammatory responses, given specific IL-1 genetic patterns, our ability to make progress in advancing our science and our ability to launch new commercial products by 2005 and those risks and uncertainties described in our annual report on Form 10-K, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements. Interleukin Genetics, Inc. Financial Highlights (unaudited) Balance sheet data March 31, December 31, 2004 2003 Cash, cash equivalents and marketable securities $ 6,494,815 $ 4,759,453 Total current assets 6,590,398 4,997,408 Total assets $7,073,371 $5,458,442 Total current liabilities 1,341,918 1,288,104 Total liabilities 3,948,852 3,900,730 Total shareholders' equity 3,124,519 1,557,712 Total liabilities and shareholders' equity $7,073,371 $5,548,442 Three Months Three Months Ended Ended March 31, March 31, Statement of operations data 2004 2003 - ----------------------------- Sales $644,943 $28,738 Gross profit 159,813 11,856 Research and development 381,260 872,439 Selling, general, and administrative expense 683,161 692,712 ------- ------- Total operating expense 1,064,421 1,565,151 Loss from operations (904,608) (1,553,295) Total other income and expense (24,354) (112,314) -------- --------- Net loss $(928,962) $(1,665,609) ========== ============ Basic and diluted loss per share $(0.04) $(0.07) Weighted average common shares outstanding 23,323,069 23,118,293 CONTACT: For Interleukin Genetics: Interleukin Genetics, Inc. Fenel M. Eloi, 781-398-0700 -----END PRIVACY-ENHANCED MESSAGE-----